University of Texas Southwestern Medical Center, Dallas, TX, USA.
LMC Diabetes & Endocrinology, Thornhill, ON, Canada.
J Diabetes Complications. 2019 Oct;33(10):107402. doi: 10.1016/j.jdiacomp.2019.06.007. Epub 2019 Jul 2.
Hypomagnesemia (serum magnesium [Mg] <0.74 mmol/L [<1.8 mg/dL]) is commonly observed in patients with type 2 diabetes (T2D). This study investigated the effect of treatment with dapagliflozin 10 mg on Mg concentrations in patients with T2D.
In this post hoc analysis, we used pooled data from 10 placebo-controlled studies of dapagliflozin over 24 weeks of treatment in patients with T2D. We evaluated the change in Mg in patients receiving dapagliflozin vs. placebo overall, and in subgroups with baseline hypomagnesemia and normal/hypermagnesemia (≥0.74 mmol/L [≥1.8 mg/dL]). We determined the proportion of patients with baseline hypomagnesemia who achieved Mg ≥0.74 mmol/L (≥1.8 mg/dL).
A total of 4398 patients with T2D were included. The mean change from baseline to week 24 in Mg was significantly larger with dapagliflozin vs. placebo; difference, 0.06 mmol/L (95% confidence interval [CI]: 0.05, 0.06). The proportion of patients with Mg within the population reference range after 24 weeks of treatment was significantly higher with dapagliflozin vs. placebo; difference, 47.8% (95% CI: 41.4, 53.9). The proportion of patients displaying hypermagnesemia did not increase with dapagliflozin treatment.
Treatment with dapagliflozin 10 mg resulted in correction of Mg concentrations in patients with T2D and hypomagnesemia.
低镁血症（血清镁[Mg]＜0.74mmol/L[＜1.8mg/dL]）在 2 型糖尿病（T2D）患者中很常见。本研究旨在探讨达格列净 10mg 治疗对 T2D 患者 Mg 浓度的影响。
在这项事后分析中，我们使用了达格列净治疗 24 周的 10 项安慰剂对照研究的汇总数据，评估了达格列净组与安慰剂组总体 Mg 变化情况，以及基线低镁血症和正常/高镁血症（≥0.74mmol/L[≥1.8mg/dL]）亚组的 Mg 变化情况。我们还确定了基线低镁血症患者中达格列净治疗后达到 Mg≥0.74mmol/L（≥1.8mg/dL）的比例。
共纳入 4398 例 T2D 患者。与安慰剂相比，达格列净治疗 24 周后 Mg 从基线的平均变化显著更大，差值为 0.06mmol/L（95%置信区间[CI]：0.05，0.06）。与安慰剂相比，达格列净治疗 24 周后 Mg 处于人群参考范围的患者比例显著更高，差值为 47.8%（95%CI：41.4，53.9）。达格列净治疗并未导致高镁血症患者比例增加。
达格列净 10mg 治疗可纠正 T2D 合并低镁血症患者的 Mg 浓度。
